Catheter Precision Stock (VTAK) Surges 170% on Delayed Investor Reaction to VIVO Product Order

Catheter Precision''s stock skyrocketed 170% in pre-market trading Wednesday as investors belatedly reacted to Monday''s announcement of a pivotal sales agreement. The medical device company secured its first purchase order for VIVO, a non-invasive 3D imaging system for ventricular arrhythmia mapping, from Sweden''s largest hospital.

Sahlgrenska University Hospital''s commitment marks a strategic win for the company, with its 350,000 annual patients and regional leadership in ventricular ablation procedures. CEO David Jenkins emphasized the long-term value of teaching hospital partnerships for physician training and future sales channels.

The explosive MOVE erased year-to-date losses but leaves shares below their 52-week peak of $6.40. Market observers note the delayed response highlights inefficient price discovery in small-cap medical technology equities.